Preview Research free. Sign in to unlock 3 full asset or company pages every day, no card needed.Sign in to unlock this page

Company profile

AbbVie

Immunology

ABBV · NYSE · USA

Share price · ABBV

$262.82+1.75 (+0.67%) 3M

close as of 2026-10-02 · 24h delayed · vol 5.9M (1.4x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Research

See what was announced around each unusual move

Research flags the days this stock moved far more than its sector fund, lists the news, filings and earnings dated around each one, and shows how much of its unusual movement fell on each asset's announcements.

Assets

(57 total)
57Total Assets
19Approved
6Phase 3 / Filed
32Phase 1–2 / Early
20Diseases
Quick filter:
Showing 57 of 57 assets
Target & Modality
adalimumab(Humira)
Approved
TNF-alphaMonoclonal antibody
Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasisRheumatoid Arthritis
Ulcerative Colitis, Crohn's Disease
Approved
Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule
Schizophrenia
Approved
—Small molecule
Migraine
Approved
Dopamine D3/D2 receptor (partial agonist)Small molecule
Major Depressive DisorderSchizophrenia
Approved
GABAergic neurotransmission
Migraine
Approved
GABAergic neurotransmissionSmall molecule
EpilepsyMigraine
Approved
SLAMF7 (CS1/CD319)Monoclonal antibody
Multiple Myeloma
Approved
dopamine precursorSmall molecule
Parkinson's Disease
Approved
dopamine precursorSmall molecule
Parkinson's Disease
Approved
Aminosalicylate
Inflammatory Bowel Disease
Ulcerative Colitis
Approved
Aminosalicylate
Inflammatory Bowel Disease
Ulcerative Colitis
Approved
Aminosalicylate
Inflammatory Bowel Disease
Ulcerative Colitis
Approved
Aminosalicylate
Inflammatory Bowel Disease
Ulcerative Colitis
Approved
Acetylcholine Release Inhibitor · acetylcholine releaseBiologic (subtype unspecified)
Migraine
risankizumab(Skyrizi)
Approved
IL-23 p19Monoclonal antibody
Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasis
Ulcerative Colitis, Crohn's Disease

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Unlock with Research ↗
Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Insider transactions

Unlock with Research ↗
Research

Unlock insider transactions

Research includes SEC Form 4 insider transactions: filed buys, sells, awards and exercises linked to the underlying filings.

Institutional holders

Unlock with Research ↗
Research

Unlock institutional holders

Research includes quarterly SEC 13F institutional ownership: top holders, aggregate positions and quarter-over-quarter context.